Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and... Read More

Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings,... Read More

New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced dsRNA, and enhanced performance SAN DIEGO / May 20, 2025 / Business Wire / TriLink BioTechnologies ® (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI), is fueling the future of mRNA research — starting with a... Read More

SAN DIEGO / May 14, 2025 / Business Wire / Today, TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance... Read More

SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a... Read More

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the... Read More

SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December... Read More

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S.... Read More

Officinae Bio's AI-driven sequence optimization expands Maravai's family of brands, enabling rapid, cost-effective nucleic acid therapy development SAN DIEGO / Feb 24, 2025 / Business Wire / Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio ’s DNA... Read More

Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink’s CleanCap mRNA capping technology for non-commercial use SAN DIEGO / Feb 04, 2025 / Business Wire / TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading,... Read More

Molecular Assemblies proprietary Fully Enzymatic Synthesis TM technology to enhance mRNA and oligonucleotide manufacturing capabilities within the TriLink BioTechnologies business SAN DIEGO / Jan 28, 2025 / Business Wire / Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and... Read More

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0... Read More

SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board,... Read More

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November. On November 19, 2024, at 8:30 a.m. PST/ 11:30 a.m. EST, Kevin Herde, Chief Financial Officer, and Drew Burch, President, Nucleic Acid Production, will participate in... Read More

Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2024, together with... Read More

Officinae Bio’s breakthroughs in AI-enabled methodologies for nucleic manufacturing to enhance Maravai’s mRNA manufacturing capabilities within the TriLink BioTechnologies business SAN DIEGO / Nov 07, 2024 / Business Wire / Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and... Read More

SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate... Read More

Drug developers & researchers can now leverage the CleanScribe enzyme to reduce dsRNA formation by up to 85% in mRNA synthesis without compromising mRNA yield, capping efficiency, or integrity SAN DIEGO / Sep 24, 2024 / Business Wire / TriLink BioTechnologies and Alphazyme , both part of Maravai LifeSciences , have collaborated to launch CleanScribe™ RNA Polymerase , a novel enzyme that reduces double-stranded RNA (dsRNA) in... Read More

Cygnus’ AccuRes Kits to recover, amplify, & quantify remaining host cell DNA during biologic drug manufacturing to produce safer, more stable vaccines, therapies, and more LELAND, N.C. & SAN DIEGO / Aug 28, 2024 / Business Wire / Cygnus Technologies (Cygnus), TriLink BioTechnologies (TriLink ® ), both part of Maravai LifeSciences (NASDAQ: MRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits.... Read More

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September. On August 14, 2024, at 11:00 a.m. PDT/ 2:00 p.m. EDT, Trey Martin, Chief Executive Officer, will participate in a panel discussion of the Critical... Read More

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $73.4 million, Net loss of $(14.5) million, and Adjusted EBITDA of... Read More

SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that its CEO William “Trey” Martin, III has been appointed to the Company’s Board of Directors, effective July 31, 2024. This strategic appointment underscores Martin’s commitment to innovation, leadership capabilities, and deep... Read More

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate... Read More

Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important for Maravai and our stakeholders. Increased the scope of greenhouse gas (GHG) emissions reporting to include select Scope 3 emissions. Expanded manufacturing production sites and launched the Analytical Sciences... Read More

The collaborative center will help to lower barriers to RNA innovation and discovery SAN DIEGO / May 13, 2024 / Business Wire / TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns... Read More

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June. On May 15, 2024, at 3:15 p.m. EST, Trey Martin, Chief Executive Officer and Kevin Herde, Chief Financial Officer, will participate in a fireside... Read More

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $64.2 million, Net loss of $(22.7) million, and Adjusted EBITDA of... Read More

Lonza customers can now access TriLink’s CleanCap ® mRNA capping technology for non-commercial use, enabling further development of critical mRNA therapeutics SAN DIEGO / Apr 30, 2024 / Business Wire / TriLink BioTechnologies (TriLink ® ), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global... Read More

cGMP Facility Streamlines Clinical & Commercial mRNA Drug Substance Development; Built by mRNA & Industry Experts to Meet Demand for mRNA-based Medicine SAN DIEGO / Apr 18, 2024 / Business Wire / TriLink BioTechnologies (TriLink ® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and... Read More

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in... Read More

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March. On March 19, 2024, at 11:15 a.m. PDT, Trey Martin, Chief Executive Officer will participate in a fireside chat at the KeyBanc Capital Markets Life... Read More

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2023, together with other business updates. Recent highlights include: Financial: Quarterly revenue of $74.1 million, Net loss of... Read More

TriLink’s CleanCap® Capping Technology is Patented Globally & TriLink is the Sole Authorized Manufacturer of CleanCap® Capping Analogs SAN DIEGO / Feb 21, 2024 / Business Wire / TriLink BioTechnologies (TriLink ® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted patents by the China National Intellectual Property Administration (CNIPA) and the... Read More

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.... Read More

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc . (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November. On November 14, 2023, at 10:55 a.m. EST, Trey Martin, Chief Executive Officer (CEO) and Kevin Herde, Chief Financial Officer (CFO), will participate... Read More

Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for... Read More

Centralized hub for advanced testing of nucleic acids to simplify mRNA drug substance testing, accelerating critical therapeutic development SAN DIEGO / Nov 02, 2023 / Business Wire / TriLink BioTechnologies ® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub. Expanding its comprehensive... Read More

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in... Read More

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, hosted its 2023 Investor R&D Day featuring presentations by Trey Martin, Chief Executive Officer, and other members of the Maravai leadership team that showcased the company’s strong foundation for growth,... Read More

SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, which recognizes the most inspiring leaders in the life sciences. Dr. Kate Broderick joined the Company in 2022 as Senior Vice... Read More

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it will host its 2023 Investor R&D Day on Thursday, September 28, starting at 10 a.m. ET in New York City. The format will feature presentations by Trey Martin, Chief Executive Officer, and other members of... Read More

LELAND, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Cygnus Technologies, part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading product and services provider for the detection and characterization of process-related impurities in biopharmaceuticals, received a 2023 R&D 100 Award from R&D World Magazine in the Analytical/Test category for the MockV ® RVLP Kit. The MockV ® RVLP Kit enables bioprocess scientists to... Read More

SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of August. On August 16, 2023, at 2:00 p.m. PDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside... Read More

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2023, together with other business updates. Recent highlights include: Quarterly revenue of $68.9 million, Net loss of $(11.9) million, and Adjusted EBITDA... Read More

William “Trey” Martin, III assumes the role of Maravai’s CEO Carl Hull to continue to serve as Executive Chairman SAN DIEGO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William “Trey” Martin, III has assumed the role of Chief Executive... Read More

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To... Read More

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Robert (“Chip”) Hance has stepped down from the Company’s Board of Directors (the “Board”) effective July 19, 2023, and that Dr. John DeFord has been appointed to the Board effective July 20,... Read More

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, recently hosted Congressman Scott Peters for a tour of the RNA manufacturing facility at Wateridge Circle in San Diego. “We were honored to host Congressman Peters at our facility in San Diego,” said Carl Hull, Executive Chairman and Interim CEO... Read More

GMP Facility Expected to Simplify the mRNA Drug Substance Development Process; Slated to Welcome Customers in Early 2024 SAN DIEGO / May 24, 2023 / Business Wire / TriLink BioTechnologies (TriLink ® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s... Read More

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing... Read More

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2023, together with other business updates. Recent highlights include: Quarterly revenue of $79.0 million, Net loss of $(1.3) million, and Adjusted EBITDA... Read More

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2023 financial and operating results after the market closes on Monday, May 8, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the... Read More

Highlights progress across five priority areas focused on building a foundation for sustainable growth. Reports Scope 1 and Scope 2 greenhouse gas emissions. Maravai advances Diversity, Equity & Inclusion and has an executive leadership team that is 50% women. SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to... Read More

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March. On March 15, 2023, at 2:00 p.m. PST, Kevin Herde, Chief Financial Officer, and Deborah Barbara, Vice President, Strategy and Business Development will... Read More

Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full year Announces acquisition of privately-held Alphazyme, LLC, adding critical enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science... Read More

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2022 financial and operating results after the market closes on Wednesday, February 22, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.... Read More